<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336785">
  <stage>Registered</stage>
  <submitdate>14/04/2011</submitdate>
  <approvaldate>9/05/2011</approvaldate>
  <actrnumber>ACTRN12611000477921</actrnumber>
  <trial_identification>
    <studytitle>Target Temperature Management after cardiac arrest Trial</studytitle>
    <scientifictitle>A multi-centre randomised, parallel group, assessor-blinded clinical trial to compare all-cause mortality between a target temperature management of 33 degrees Celsius versus a target temperature management of 36 degrees Celsius after out-of-hospital cardiac arrest</scientifictitle>
    <utrn />
    <trialacronym>TTM-Trial</trialacronym>
    <secondaryid>ClinicalTrials.gov: NCT01020916</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Out-of-hospital cardiac arrest</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Target temperature of 33 degrees Celsius.

Patients will be managed with 24 hours of temperature control at a target temperature of 33 degrees Celsius. Temperature management will be delivered with commercially available equipment at the discretion of each trial site. The type of equipment used for a specific patient will be registered prior to randomisation. When applicable, to facilitate cooling and to stabilise circulation, patients will be treated with crystalloid infusion (4 degrees Celsius or room temperature according to treatment arm) at the discretion of the treating physician. 

Intervention period begins when the first temperature measurement to achieve the assigned target temperature, is taken. Patients are mechanically ventilated and sedated as per standard practice. Patients are treated for 24 hours with temperature management devices to achieve a target temperature of 33 degrees Celsius. Patients are then rewarmed to a body temperature of 37 degrees Celsius within the following 8 hours, with a rewarming rate of 0.5 degrees per hour.

Sedation will be ceased or tapered once temperature reaches 37 degrees Celsius. Normothermia of 37 degrees  +/- 0.5 degrees Celsius is maintained for 36 hours.</interventions>
    <comparator>Target temperature of 36 degrees Celsius</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>All-cause mortality</outcome>
      <timepoint>180 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Composite outcome of all-cause mortality and poor neurological function (CPC 3 and 4)</outcome>
      <timepoint>Hospital discharge and at 180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All-cause mortality</outcome>
      <timepoint>Hospital discharge</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cerebral Performance Category (CPC)</outcome>
      <timepoint>Hospital discharge and at 180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Neurological function will be assessed by an assessor blinded to the intervention allocation. 

Quality of life assessment will also be evaluated by the blinded assessor, using Mini Mental Test, IQCODE, Modified Rankin Scale and Short Form 36.

These follow up assessments attended by the blinded assessor will be performed via a telephone call to the patient and/or the patient's substitute decision maker.</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Best neurological outcome according to the CPC-scale</outcome>
      <timepoint>Baseline until 180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety measures: Bleeding, pneumonia, sepsis, electrolyte disorders, hyperglycaemia, hypoglycaemia, cardiac arrhythmia and the need for renal replacement therapy.

All adverse events will be recorded daily for the first 7 days, whilst the patient is in the ICU. Any adverse event occurring during the trial will be treated according to standard practice and the patient will be followed until the event has disappeared or until the condition has stabilised. 
 
All adverse events (AE, SAE, SUSAR) are reviewed by the Data Safety Monitoring Board.</outcome>
      <timepoint>Baseline until 7 days (whilst patient in ICU)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Age greater than or equal to 18 years
2. OHCA of presumed cardiac cause
3. Sustained ROSC*
4. Unconsciousness (GCS &lt;8) (patients not able to obey verbal commands) after sustained ROSC

* Sustained ROSC: Sustained ROSC is when chest compressions have been not required for 20 consecutive minutes and signs of circulation persist</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Conscious patients (obeying verbal commands)
2. Pregnancy
3. In-hospital cardiac arrest (IHCA)
4. OHCA of presumed non-cardiac cause, e.g. after trauma or dissection/rupture of major artery OR Cardiac arrest caused by initial hypoxia (i.e. drowning, suffocation, hanging)
5. Known bleeding diathesis (medically induced coagulopathy e.g. warfarin, clopidogrel, does not exclude the patient)
6. Suspected or confirmed acute intracranial bleeding
7. Suspected or confirmed acute stroke
8. Unwitnessed asystole
9. A limitation of therapy order has been documented restricting implementation of the study protocol or the treating clinician deems aggressive care unsuitable
10. Known underlying disease making 180 day survival unlikely
11. Known pre-arrest CPC 3 or 4
12. &gt;4 hours (240 minutes) from ROSC to screening
13. Systolic blood pressure &lt;80 mmHg in spite of fluid loading/vasopressor and/or inotropic medication/intra aortic balloon pump#
14. Temperature on admission &lt;30 degrees Celsius</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation via website. 
Allocation is not concealed from treating clinicians.</concealment>
    <sequence>Randomisation will be achieved by dynamic blocks via a password-protected encrypted website. Randomisation will be stratified according to participating trial site.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/12/2010</anticipatedstartdate>
    <actualstartdate>1/01/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate>11/01/2013</actualenddate>
    <samplesize>850</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2170</postcode>
    <postcode>2560</postcode>
    <postcode>2622</postcode>
    <postcode>2065</postcode>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Helsingborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Lund</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Malmo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>karlstad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Linkoping</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Molndal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Norrkoping</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Gothenburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Orebro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Prague</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Copenhagen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Gentofte</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bonn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Iceland</country>
      <state>Reykjavik</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Trento</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Trieste</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pordenone</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Siena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Luxembourg</country>
      <state>Luxembourg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>leeuwarden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Bergen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Geneva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>lausanne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cardiff</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Reading</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Dorset</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Helsingborg Hospital</primarysponsorname>
    <primarysponsoraddress>S Vallgatan 5
S-251 87 Helsingborg
Lund University
Lund</primarysponsoraddress>
    <primarysponsorcountry>Sweden</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Swedish Heart and Lung Foundation</fundingname>
      <fundingaddress>Box 5413
Biblioteksgatan 29
SE 114 84 Stockholm</fundingaddress>
      <fundingcountry>Sweden</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>AFA-Foundation</fundingname>
      <fundingaddress>Klara Sodra Kyrkogata 18
SE 106 27 Stockholm</fundingaddress>
      <fundingcountry>Sweden</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Stig and Ragna Gorthon Foundation</fundingname>
      <fundingaddress>Box 1417, Storgatan 16, 3tr
SE 251 14 Helsingborg</fundingaddress>
      <fundingcountry>Sweden</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Gyllenstierna Krapperup Foundation</fundingname>
      <fundingaddress>Krapperups Kyrkovag 13
SE 260 41 Nyhamnslage</fundingaddress>
      <fundingcountry>Sweden</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>ACTA Foundation within the Scandinavian Society of Anaesthesiology and Intensive Care</fundingname>
      <fundingaddress>c/o Mr Henrik Wedell-Wedellsborg, Lawyer
Hjejle, Gersted and Mogensen Law Firm
24, Amagertorv
DK 1160, Copenhagen</fundingaddress>
      <fundingcountry>Denmark</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Torsten Birger Segerfalk Foundation</fundingname>
      <fundingaddress>c/o Lund University
Box 117
SE 221 00 Lund</fundingaddress>
      <fundingcountry>Sweden</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Region Skane</fundingname>
      <fundingaddress>Skanehuset i Kristianstad
JA Hedlunds vag
SE 291 89 Kristianstad</fundingaddress>
      <fundingcountry>Sweden</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Governmental funding for clinical research</fundingname>
      <fundingaddress>Socialstyrelsen
SE 106 30 Stockholm</fundingaddress>
      <fundingcountry>Sweden</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Scandinavian Critical Care Trials Group</sponsorname>
      <sponsoraddress>Hjejle, Gersted and Mogensen Law Firm
24, Amagertorv
DK 1160, Copenhagen</sponsoraddress>
      <sponsorcountry>Denmark</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Copenhagen Trial Unit, Centre for Clinical Intervention Research</sponsorname>
      <sponsoraddress>Rigshospitalet
Dept. 33.44 
DK-2100
Copenhagen</sponsoraddress>
      <sponsorcountry>Denmark</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>The George Institute for Global Health</othercollaboratorname>
      <othercollaboratoraddress>Level 7
341 George Street
Sydney NSW 2000</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Experimental studies and previous clinical trials suggest an improvement in mortality and neurological function with hypothermia after cardiac arrest. However, the accrued evidence is inconclusive and associated with risks of systematic error, design error and random error. Elevated body temperature after cardiac arrest is associated with a worse outcome. Previous trials did not treat elevated body temperature in the control groups. The optimal target temperature for post-resuscitation care is not known. The primary purpose with the TTM-trial is to evaluate if there are differences in all-cause mortality, neurological function and adverse events between a target temperature management at 33 degrees Celsius and 36 degrees Celsius for 24 hours following return of spontaneous circulation after cardiac arrest.</summary>
    <trialwebsite>http://www.ttm-trial.org/</trialwebsite>
    <publication>Nielsen N, Wetterslev J, al-Subaie N, Andersson B, Bro-Jeppesen J, Bishop G, Brunetti L, MD, Cranshaw J, Cronberg T, Edqvist K, Erlinge D, Gasche Y, Glover G, Hassager C, Horn J, Hovdenes J,  Johnsson J, Kjaergaard J, Kuiper M, Langorgen J, Macken L, Martinell L, Martner P, Pellis T, Pelosi P, MD, Petersen P, Persson S, Rundgren M, Saxena M, Svensson R, Stammet P, Thoren A, Unden J, Walden A, Wallskog J, Wanscher M, Wise MP, Wyon N, Aneman A, and Friberg. Target temperature management after out-of-hospital cardiac arresta randomized, parallel-group, assessor-blinded clinical trialrationale and design. American Heart Journal. 2012; 163: 541-548

Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, Horn J, Hovdenes J, Kjaergaard J, Kuiper M, Pellis T, Stammet P, Wanscher M, Wise MP,  Aneman A, Al-Subaie N, Boesgaard S, Bro-Jeppesen J, Brunetti I, Bugge JF, Hingston CD,  Juffermans NP, Koopmans M, Kober L, Langorgen J, Lilja G, Moller JE, Rundgren M, Rylander C, Smid O, Werer C, Winkel P, and Friberg H,  for the TTM Trial Investigators. Targeted Temperature Management at 33 degrees Celsius versus 36 degrees Celsius after Cardiac Arrest. N Eng J Med November 17 2013</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Research Ethics Committee for Wales</ethicname>
      <ethicaddress>Sixth floor, Churchill House
17 Churchill Way
Cardiff, CF10 2TW</ethicaddress>
      <ethicapprovaldate>21/12/2010</ethicapprovaldate>
      <hrec>10/MRE09/41</hrec>
      <ethicsubmitdate>22/11/2010</ethicsubmitdate>
      <ethiccountry>United Kingdom</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>National Ethics Research Committee</ethicname>
      <ethicaddress>1a-1b rue Thomas Edison
L-1445 Luxembourg</ethicaddress>
      <ethicapprovaldate>12/07/2010</ethicapprovaldate>
      <hrec>201007/05</hrec>
      <ethicsubmitdate>22/06/2010</ethicsubmitdate>
      <ethiccountry>Luxembourg</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Medical Ethics Research Committee</ethicname>
      <ethicaddress>Academic Medical Centre (AMC)
University of Amsterdam
Meibergdreef 9
1105 AZ  Amsterdam</ethicaddress>
      <ethicapprovaldate>22/11/2010</ethicapprovaldate>
      <hrec>1/10/0107</hrec>
      <ethicsubmitdate />
      <ethiccountry>Netherlands</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Regional Ethics Research Committee</ethicname>
      <ethicaddress>Lund University
Ostra Vallgatan 14
Ostervangsgatan 1
Lund</ethicaddress>
      <ethicapprovaldate>11/11/2010</ethicapprovaldate>
      <hrec>2010/615</hrec>
      <ethicsubmitdate />
      <ethiccountry>Sweden</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Science Committee of Capital Region</ethicname>
      <ethicaddress>Kongens Vaenge 2
2400 Hillerod</ethicaddress>
      <ethicapprovaldate>27/09/2010</ethicapprovaldate>
      <hrec>H-1-2010-059</hrec>
      <ethicsubmitdate>21/09/2010</ethicsubmitdate>
      <ethiccountry>Denmark</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Regional Research Ethics Committee</ethicname>
      <ethicaddress>Medical Faculty
University of Oslo
Postboks 1130 Blindern
NO-0318 
Oslo</ethicaddress>
      <ethicapprovaldate>15/06/2010</ethicapprovaldate>
      <hrec>2010/384</hrec>
      <ethicsubmitdate>25/02/2010</ethicsubmitdate>
      <ethiccountry>Norway</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Independent Ethics Committee of Azienda Hospital</ethicname>
      <ethicaddress>33170 Pordernone
via Montereale, 24</ethicaddress>
      <ethicapprovaldate>2/03/2011</ethicapprovaldate>
      <hrec>9</hrec>
      <ethicsubmitdate>22/11/2010</ethicsubmitdate>
      <ethiccountry>Italy</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Ethics Committee for Clinical Trials</ethicname>
      <ethicaddress>Azienda Province Health Service
via Degasperi, 79
38123 Trento</ethicaddress>
      <ethicapprovaldate>10/02/2011</ethicapprovaldate>
      <hrec>19292694</hrec>
      <ethicsubmitdate />
      <ethiccountry>Italy</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Ethics Committee of the General University Hospital, Prague</ethicname>
      <ethicaddress>Na Bojisti 1
128 08 Praha 2
Prague</ethicaddress>
      <ethicapprovaldate>17/02/2011</ethicapprovaldate>
      <hrec>193/11 S</hrec>
      <ethicsubmitdate>7/02/2011</ethicsubmitdate>
      <ethiccountry>Czech Republic</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Research Ethics Committee</ethicname>
      <ethicaddress>NAC Department
University Hospital of Geneva
1211 Geneva 14</ethicaddress>
      <ethicapprovaldate>1/03/2011</ethicapprovaldate>
      <hrec>10-254 (NAC 10-088)</hrec>
      <ethicsubmitdate>14/02/2011</ethicsubmitdate>
      <ethiccountry>Switzerland</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/336785-TTM Publication_Rationale &amp; Design_Apr 2012.pdf</filepath>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/336785-TTM_Results Publication_NEJMoa1310519.pdf</filepath>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/336785-TTM_Results Publication_NEJMoa1310519_Appendices.pdf</filepath>
  </attachment>
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dr Niklas Nielsen</name>
      <address>Department of Anaesthesiology and Intensive Care
Helsingborg Hospital 
S Vallgatan 5
S-251 87 Helsingborg
Lund University
Lund</address>
      <phone>+ 46 4 2406 1000</phone>
      <fax />
      <email>niklas.nielsen@telia.com</email>
      <country>Sweden</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>A/Prof Anders Aneman</name>
      <address>Intensive Care Unit
Liverpool Hospital
Locked Bag 7103
Liverpool BC NSW 1871</address>
      <phone>+61 2 8738 3400</phone>
      <fax>+61 2 8738 3551</fax>
      <email>Anders.Aneman@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sharon Micallef</name>
      <address>Intensive Care Unit
Liverpool Hospital
Locked Bag 7103
Liverpool BC NSW 1871</address>
      <phone>+61 2 8738 3193</phone>
      <fax>+61 2 8738 3551</fax>
      <email>Sharon.Micallef@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Anders Aneman</name>
      <address>Intensive Care Unit 
Liverpool Hospital 
Locked Bag 7103 
Liverpool BC NSW 1871</address>
      <phone>+61 2 8738 3400</phone>
      <fax />
      <email>Anders.Aneman@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>